These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10444287)

  • 1. Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A.
    Hay JW; Ernst RL; Kessler CM
    Haemophilia; 1999 May; 5(3):191-202. PubMed ID: 10444287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A.
    Lotfi F; Talebianpour H; Keshavarz K; Emadi F; Bordbar MR; Bastani P
    Daru; 2020 Jun; 28(1):287-293. PubMed ID: 32323144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic products and difficult decisions. The case of recombinant factor VIII in the management of haemophilia A.
    Green C; Akehurst R
    J Public Health Med; 1998 Jun; 20(2):137-8. PubMed ID: 9675729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study.
    Goedert JJ; Cohen AR; Kessler CM; Eichinger S; Seremetis SV; Rabkin CS; Yellin FJ; Rosenberg PS; Aledort LM
    Lancet; 1994 Sep; 344(8925):791-2. PubMed ID: 7916077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy.
    Coppola A; D'Ausilio A; Aiello A; Amoresano S; Toumi M; Mathew P; Tagliaferri A;
    Haemophilia; 2017 May; 23(3):422-429. PubMed ID: 28181369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
    Lorenzoni V; Triulzi I; Turchetti G
    BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating haemophilia A with recombinant blood factors: a comparison.
    Ananyeva N; Khrenov A; Darr F; Summers R; Sarafanov A; Saenko E
    Expert Opin Pharmacother; 2004 May; 5(5):1061-70. PubMed ID: 15155108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
    Amiral J; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemophilia A in two premature infants.
    Bidlingmaier C; Bergmann F; Kurnik K
    Eur J Pediatr; 2005 Feb; 164(2):70-2. PubMed ID: 15580358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates.
    Meeks SL; Josephson CD
    Curr Opin Hematol; 2006 Nov; 13(6):457-61. PubMed ID: 17053459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor.
    Croteau SE; Abajas YL; Wolberg AS; Nielsen BI; Marx GR; Baird CW; Neufeld EJ; Monahan PE
    Haemophilia; 2017 Mar; 23(2):e93-e98. PubMed ID: 28124406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery.
    Rochat C; McFadyen ML; Schwyzer R; Gillham A; Cruickshank A
    Haemophilia; 1999 May; 5(3):181-6. PubMed ID: 10444285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries.
    O'Mahony B; Noone D; Prihodova L
    Haemophilia; 2015 Jul; 21(4):436-43. PubMed ID: 25996253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.